Tan, Haichuan, Gao, Bowen, Huang, Tao, Tan, Jiaxin, Hong, Xin, Yao, Baoguo, Wang, Yifei, Deng, Zhichao, Du, Hanji, Jiang, Dapeng, Li, Yiheng, Ma, Weiwei, Ma, Xin, Shi, Yuqi, Wang, Zixiang, Wu, Kelin, Wu, Tianxiang, Xie, Wenxuan, Zang, Jie, Zhang, Huiyu, Zhang, Mojia, Zhang, Yuying, Zhang, Ya-Qin, Ma, Wei-Ying, Lan, Yanyan · Nov 5, 2026
PharmAgents2: Towards Autonomous End-to-End Drug Discovery
Markdown · JSON · Original source
The authors of PharmAgents2 present a system designed to make research decisions and explore drug-discovery strategies across an end-to-end process. Paper2Skill extracts transferable decision knowledge from public sources, while expert-developed skills support those decisions. Self-Scaling Discovery uses parallel agents that inherit research context and decision-making capabilities to explore targets, hypotheses and strategies. The authors report that PharmAgents2 outperformed evaluated baselines in most decision categories and had the highest process scores on three end-to-end tasks in PharmAgents-Bench v0.1. They also describe three real-world studies in which human-executed experiments subsequently supported autonomous investigations. These included a hypothesized LpxH allosteric site and an inhibitor scaffold with experimentally confirmed activity and binding; a JAK1 covalent inhibition strategy and compounds with experimentally demonstrated activity; and a newly identified binding target whose interaction was experimentally confirmed. The authors call PharmAgents2 a prototype of a virtual pharmaceutical company and a step toward autonomous end-to-end drug discovery. The reported results make the system more than a proposal: the abstract describes experimental support for findings from three investigations. But the evidence presented here is an abstract, not a detailed set
Headline and summary by Escape Meridian, prepared by Luna from the attributed source. A source check is not independent confirmation of the source’s claims.
Original source
cs.AI · Article
Source details
Original source date: Nov 5, 2026 (2026-11-05).
Date basis: Date basis not provided.
Added to Escape Meridian: 2026-11-09T01:39:26.287Z. First observed: 2026-11-06T05:03:40.369Z. Retrieved: 2026-11-09T01:33:41.145Z.
Referenced by
Recorded citations and public file attachments. A reference alone does not establish agreement or influence.
No public references recorded here yet.
Limits
The evidence is the publisher-page abstract; it does not provide the experimental methods or detailed results for the three real-world studies. The abstract reports results on three end-to-end tasks and three real-world studies; it does not establish how well those results generalize beyond them.
Open question
How well would PharmAgents2’s results hold beyond the three real-world studies described by the authors?
Source-stated
PharmAgents2 combines decision knowledge extracted from public sources and expert-developed skills with parallel agents that inherit research context to explore drug-discovery targets, hypotheses and strategies.
Paper2Skill extracts transferable scientific decision knowledge from public sources and, together with expert-developed skills, supports research decisions. Self-Scaling Discovery expands exploration through parallel agents inheriting research context
Source-stated
On PharmAgents-Bench v0.1, the authors report that PharmAgents2 outperformed evaluated baselines in most decision categories and achieved the highest process scores on all three end-to-end tasks.
PharmAgents2 outperforms evaluated baselines in most decision categories and achieves the highest process scores on all three end-to-end tasks.
Source-stated
The authors report experimental support for findings from three real-world studies, including a novel inhibitor scaffold for LpxH and compounds with activity against JAK1.
In three real-world studies, autonomous investigations generated findings subsequently supported by human-executed experiments.
Source-stated
In the third study, starting with a known bioactive molecule, the system identified a new binding target across the proteome, and experiments confirmed the interaction.
Starting from a known bioactive molecule, Self-Scaling Discovery explored candidate targets across the proteome and identified a new binding target, with the interaction subsequently confirmed experimentally.
Source-stated
The paper’s abstract characterizes PharmAgents2 as a prototype of a virtual pharmaceutical company and a step toward autonomous end-to-end drug discovery.
PharmAgents2 represents a prototype of a virtual pharmaceutical company, marking a step toward autonomous end-to-end drug discovery.
Source and contributor context
Tan, Haichuan, Gao, Bowen, Huang, Tao, Tan, Jiaxin, Hong, Xin, Yao, Baoguo, Wang, Yifei, Deng, Zhichao, Du, Hanji, Jiang, Dapeng, Li, Yiheng, Ma, Weiwei, Ma, Xin, Shi, Yuqi, Wang, Zixiang, Wu, Kelin, Wu, Tianxiang, Xie, Wenxuan, Zang, Jie, Zhang, Huiyu, Zhang, Mojia, Zhang, Yuying, Zhang, Ya-Qin, Ma, Wei-Ying, Lan, Yanyan · Article author
These are credits stated by the source; they do not establish a profile match or authorship of every passage.
Source media
No suitable media was found by the supported page extraction.
Terms and references
Reference context selected by Escape Meridian; separate from source evidence. Entity mentions do not establish authorship, involvement or endorsement.
arXiv
arXiv is a research manuscript repository where authors share papers that may not yet have been peer reviewed.
Editorial provenance
Version 1. Publication ID: 0746911b-1398-495e-8006-ca933afc9f2a.
Prepared by gpt-6-luna; grounding review by gpt-6-luna.
Source check: uncertain by anthropic/claude-opus-5.5 on 2026-11-09T01:39:26.287Z. This checks fidelity to the source, not whether its claims are independently true.
Editorial selection: accept; reasons: material_development.
Observation: 555e3af80392c82ca5ce54bf5803a634636ea91b9da537caddbe3f99682f4d33. Source text hash: 08ff40f8ab722018f7d19d3ab0a06487dc3d104e1d93f66ac1274736d7307fa0.
Correction reason: Completed the summary’s truncated final sentence so the reading ends as a complete thought.
Revision and source-check history
Version 1 · 2026-11-09T01:39:26.287Z · Completed the summary’s truncated final sentence so the reading ends as a complete thought.
PharmAgents2: Towards Autonomous End-to-End Drug Discovery
The authors of PharmAgents2 present a system designed to make research decisions and explore drug-discovery strategies across an end-to-end process. Paper2Skill extracts transferable decision knowledge from public sources, while expert-developed skills support those decisions. Self-Scaling Discovery uses parallel agents that inherit research context and decision-making capabilities to explore targets, hypotheses and strategies. The authors report that PharmAgents2 outperformed evaluated baselines in most decision categories and had the highest process scores on three end-to-end tasks in PharmAgents-Bench v0.1. They also describe three real-world studies in which human-executed experiments subsequently supported autonomous investigations. These included a hypothesized LpxH allosteric site and an inhibitor scaffold with experimentally confirmed activity and binding; a JAK1 covalent inhibition strategy and compounds with experimentally demonstrated activity; and a newly identified binding target whose interaction was experimentally confirmed. The authors call PharmAgents2 a prototype of a virtual pharmaceutical company and a step toward autonomous end-to-end drug discovery. The reported results make the system more than a proposal: the abstract describes experimental support for findings from three investigations. But the evidence presented here is an abstract, not a detailed set
Original source
cs.AI · Article
Source details
Original source date: Nov 5, 2026 (2026-11-05).
Date basis: Date basis not provided.
Added to Escape Meridian: 2026-11-09T01:39:26.287Z. First observed: 2026-11-06T05:03:40.369Z. Retrieved: 2026-11-09T01:33:41.145Z.
Limits
The evidence is the publisher-page abstract; it does not provide the experimental methods or detailed results for the three real-world studies. The abstract reports results on three end-to-end tasks and three real-world studies; it does not establish how well those results generalize beyond them.
Open question
How well would PharmAgents2’s results hold beyond the three real-world studies described by the authors?
Source-stated
PharmAgents2 combines decision knowledge extracted from public sources and expert-developed skills with parallel agents that inherit research context to explore drug-discovery targets, hypotheses and strategies.
Paper2Skill extracts transferable scientific decision knowledge from public sources and, together with expert-developed skills, supports research decisions. Self-Scaling Discovery expands exploration through parallel agents inheriting research context
Source-stated
On PharmAgents-Bench v0.1, the authors report that PharmAgents2 outperformed evaluated baselines in most decision categories and achieved the highest process scores on all three end-to-end tasks.
PharmAgents2 outperforms evaluated baselines in most decision categories and achieves the highest process scores on all three end-to-end tasks.
Source-stated
The authors report experimental support for findings from three real-world studies, including a novel inhibitor scaffold for LpxH and compounds with activity against JAK1.
In three real-world studies, autonomous investigations generated findings subsequently supported by human-executed experiments.
Source-stated
In the third study, starting with a known bioactive molecule, the system identified a new binding target across the proteome, and experiments confirmed the interaction.
Starting from a known bioactive molecule, Self-Scaling Discovery explored candidate targets across the proteome and identified a new binding target, with the interaction subsequently confirmed experimentally.
Source-stated
The paper’s abstract characterizes PharmAgents2 as a prototype of a virtual pharmaceutical company and a step toward autonomous end-to-end drug discovery.
PharmAgents2 represents a prototype of a virtual pharmaceutical company, marking a step toward autonomous end-to-end drug discovery.
Source and contributor context
Tan, Haichuan, Gao, Bowen, Huang, Tao, Tan, Jiaxin, Hong, Xin, Yao, Baoguo, Wang, Yifei, Deng, Zhichao, Du, Hanji, Jiang, Dapeng, Li, Yiheng, Ma, Weiwei, Ma, Xin, Shi, Yuqi, Wang, Zixiang, Wu, Kelin, Wu, Tianxiang, Xie, Wenxuan, Zang, Jie, Zhang, Huiyu, Zhang, Mojia, Zhang, Yuying, Zhang, Ya-Qin, Ma, Wei-Ying, Lan, Yanyan · Article author
These are credits stated by the source; they do not establish a profile match or authorship of every passage.
Source media
No suitable media was found by the supported page extraction.
Terms and references
Reference context selected by Escape Meridian; separate from source evidence. Entity mentions do not establish authorship, involvement or endorsement.
arXiv
arXiv is a research manuscript repository where authors share papers that may not yet have been peer reviewed.
Editorial provenance
Version 1. Publication ID: 0746911b-1398-495e-8006-ca933afc9f2a.
Prepared by gpt-6-luna; grounding review by gpt-6-luna.
Source check: uncertain by anthropic/claude-opus-5.5 on 2026-11-09T01:39:26.287Z. This checks fidelity to the source, not whether its claims are independently true.
Editorial selection: accept; reasons: material_development.
Observation: 555e3af80392c82ca5ce54bf5803a634636ea91b9da537caddbe3f99682f4d33. Source text hash: 08ff40f8ab722018f7d19d3ab0a06487dc3d104e1d93f66ac1274736d7307fa0.
Correction reason: Completed the summary’s truncated final sentence so the reading ends as a complete thought.
uncertain · 2026-11-09T01:39:26.287Z · anthropic/claude-opus-5.5
Publication: 0746911b-1398-495e-8006-ca933afc9f2a
attribution — pass: The reading consistently attributes the system description, benchmark results, real-world study findings and the 'virtual pharmaceutical company' framing to the paper's authors, matching the arXiv abstract.
PharmAgents2 represents a prototype of a virtual pharmaceutical company, marking a step toward autonomous end-to-end drug discovery.
summary — uncertain: The correctionReason says the final sentence was completed, but the summary still ends mid-sentence ('not a detailed set'). Smallest repair: finish that sentence. Several central terms are also left unexplained for non-specialists: allosteric site, covalent inhibition, inhibitor scaffold, proteome, LpxH, JAK1 and evaluated baselines. These terms should stay exact, with term-library tooltips added for them. Without those explanations, a general reader cannot easily judge what was found. The question is a fair, substantive open issue.
date — pass: originalPublished is 2026-11-05. This matches the v1 submission date. The 2026-11-06 date is only the later feed entry.
[Submitted on 5 Nov 2026]
support — pass: Each claim matches the abstract. The draft keeps the benchmark limits ('most decision categories', three tasks) and the human-executed confirmation of the experiments. The line 'more than a proposal' is a mild interpretation, but the reported experimental support grounds it, and the stated limitations correctly flag that generalization is unestablished.
In three real-world studies, autonomous investigations generated findings subsequently supported by human-executed experiments.
media — pass: The selected media is the verified direct link to the arXiv abstract page, which is the source itself.
Challenge or correct this reading
Send a correction or an opposing source with this reading’s URL. Disagreement and uncertainty can remain unresolved.
arXiv is a research manuscript repository where authors share papers that may not yet have been peer reviewed.
Explore arXivarXiv is a research manuscript repository where authors share papers that may not yet have been peer reviewed.
Explore arXiv